A new daily pill, orforglipron, may soon be available in the UK to help individuals maintain weight loss after stopping obesity injections. Research indicates that this pill can help users retain over 70% of their weight loss, significantly reducing the risk of regaining weight, a common issue when discontinuing GLP-1 injections.
Orforglipron mimics a hormone that suppresses appetite, similar to existing injectable treatments. While it is currently available in the US at a lower cost than injections, the price in the UK remains unknown. This could potentially make weight management more accessible for many, especially as obesity is increasingly recognised as a chronic condition requiring ongoing treatment.
For UK residents, the introduction of orforglipron could mean a more manageable and less invasive option for weight maintenance, which may alleviate some of the financial burden associated with long-term obesity treatments. This could also lead to improved health outcomes, reducing the risk of obesity-related diseases.
As the UK awaits the official launch, it will be important to monitor pricing and availability. Additionally, further studies will be needed to understand the long-term effects and the necessity of continued treatment for optimal results.
Sources
BBC News
